Prana Biotechnology (PRAN)

[BONGWHOLE]

$ PRAN $----THIS IS THE REASON, FOR THE DROP IN MARCH 2014:


Prana Biotechnology - A Gamble Worth Taking For Both Long- And Short-Term Investors
Ray DeLuca • Thu, Mar. 20 • 117 Comments
An approved Alzheimer's drug for disease modification will generate at least $5 billion a year in revenue on average, as no drugs currently exist.
LMTX from TauRx, Crenezumab from Roche, and PBT2 from Prana are best-positioned to succeed; PBT2 has the best overall position.
Prana's previous trials have been unimpressive, but hidden inside those results are clues to a highly-effective drug.
Prana stock is significantly undervalued, but is unlikely to remain so after releasing Phase IIb Alzheimer's results later this month.
The company's current cash position is AU$25.4M.

BUT, THIS IS A NEW DAY, FOR PRAN:

http://www.thestreet.com/story/12868544/1/why-prana-biotechnology-pran-stock-is-surging-today.html

$$ PRAN $$